Target intelligence / Profile preview

Autophagy degradation machinery

Molecular classification
Enzyme, Receptor, Transcription factor, Other (Protein complex)
01

Overview

The autophagy degradation machinery is a highly conserved catabolic process responsible for the degradation and recycling of cytoplasmic components, including damaged organelles and misfolded proteins, via the lysosomal pathway [Mizushima et al., 2011, Cell]. This machinery is orchestrated by a series of autophagy-related (ATG) proteins that facilitate the formation of double-membrane vesicles called autophagosomes, which subsequently fuse with lysosomes for cargo digestion [Dikic & Elazar, 2018, Nat Rev Mol Cell Biol]. It serves as a critical quality control mechanism, maintaining cellular homeostasis under basal conditions and providing energy during nutrient deprivation [Levine & Kroemer, 2019, Cell]. Dysregulation of this machinery is implicated in a wide range of pathologies, including neurodegenerative diseases where protein aggregates accumulate, and cancer, where it plays a dual role as both a tumor suppressor and a survival mechanism for established tumors [Galluzzi et al., 2017, Nat Rev Drug Discov]. Therapeutic strategies involve either inducing autophagy to clear toxic aggregates or inhibiting it to sensitize cancer cells to chemotherapy [Klionsky et al., 2021, Autophagy].

Other names
MacroautophagyAutophagic pathwayLysosomal degradation pathwayATG-dependent degradation
02

Mechanism of action

Modulation of the autophagy pathway through mTOR inhibition (induction), PI3K inhibition (blockade of initiation), or lysosomal acidification blockade (blockade of degradation).

03

Biological functions

Protein degradationCellular homeostasisOrganelle turnoverNutrient recyclingStress response
04

Disease associations

CancerNeurodegenerative diseaseInfectionInflammationCardiovascular disease
05

Safety considerations

Systemic toxicity due to ubiquitous role in cellular homeostasisPotential to promote tumor survival in advanced cancer stagesImmunosuppression associated with mTOR inhibitorsLysosomal storage issues
06

Interacting drugs

Sirolimus (Rapamycin)

6 more in the full profile.

07

Biomarkers

Microtubule-associated protein 1 light chain 3 beta (LC3-II)Sequestosome 1 (p62/SQSTM1)Autophagic fluxATG protein expression levels

Beyond the preview

Go deeper on Autophagy degradation machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autophagy degradation machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call